Garivulimab Biosimilar - Research Grade

Out of stock

Only %1 left

SKU

ICH5565-10mg

Add to Compare

Be the first to review this product

Garivulimab Biosimilar - Research Grade

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>90% by SDS-PAGE

Species Reactivity

Human

Target

PD-L1

Concentration

>1mg/ml

Isotype

IgG1 - kappa

Host

CHO Cells

Antibodies Against The Same Target

Sequence

https://www.imgt.org/mAb-DB/

Buffer

ICH3002

Uniprot

Q9NZQ7

Shipping Conditions

Blue ice

Background

This product is an unconjugated, non-therapeutic recombinant analog of garivulimab (originator code BGB-A333), a monoclonal antibody built around the immune-checkpoint ligand PD-L1 (CD274/B7-H1). It is supplied for research use only and is not the clinical drug, nor is it intended for human or veterinary use. The molecule reproduces the antigen specificity of the originator (human PD-L1, UniProt Q9NZQ7) on a human IgG1/kappa framework, making it a useful reagent for interrogating the PD-1/PD-L1 axis in a controlled setting. Typical research applications include serving as a defined positive control or benchmarking standard in checkpoint-blockade assays, as a capture or detection reagent for PD-L1, as a tool for characterizing PD-L1 expression and ligand-blocking activity, and as a starting antibody for ADCC or antibody-drug-conjugate development workflows. It is offered in low-endotoxin, in-vivo-grade formats (research grade less than 1 EU/mg; ultra-low less than 0.5 EU/mg) and in bulk milligram-to-gram quantities to support reproducible, scalable in-vitro and preclinical work. PD-L1 (Programmed Death-Ligand 1; also CD274 or B7-H1; UniProt Q9NZQ7) is a type I transmembrane glycoprotein of the B7 family and a key ligand of the immune checkpoint system. It is expressed on antigen-presenting cells, various normal tissues, and is frequently upregulated on tumor cells and in the tumor microenvironment, often in response to interferon-gamma. Engagement of PD-L1 with its receptor PD-1 on activated T cells delivers an inhibitory signal that dampens T-cell receptor signaling, reduces proliferation and cytokine production, and promotes T-cell exhaustion. PD-L1 also binds CD80 (B7-1) in a distinct cis/trans interaction that further modulates T-cell activation. By co-opting this pathway, tumors evade cytotoxic T-lymphocyte responses, which is why PD-L1 is a central target for checkpoint-blockade immunotherapy research.

Other Names

CD274

Purification Method

This monoclonal antibody was purified using Protein A

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Storage

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications

Functional Assays

Application Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.